Comparison of Pharmacokinetics of Long-Acting Local Analgesics: CPL-01, a Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Exposure Compared with Liposomal Bupivacaine.

Clinical drug investigation 2025 Vol.45(2) p. 51-58

Pope S, Crean C, Thrasher S, Xu H, Chen PJ, Chen L, Hu D, Onel E

관련 도메인

Abstract

[BACKGROUND AND OBJECTIVE] There is a significant medical need for improved long-acting local anesthetics to decrease postsurgical pain and reduce postoperative opioid use. While ropivacaine is considered a safer local anesthetic than bupivacaine, no long-acting ropivacaine formulation is currently marketed. Available formulations of bupivacaine show inconsistent pharmacokinetics (PK) among different surgical models, and inconsistency in PK may lead to a reluctance to use the medication owing to fear of local anesthetic systemic toxicity (LAST) or unreliable efficacy. CPL-01 is a novel extended-release formulation of ropivacaine. This analysis used existing published literature to compare the PK of CPL-01 and liposomal bupivacaine (LB) across five surgical models.

[METHODS] Published results of LB PK were used to construct dose-normalized curves in total knee arthroscopy, hemorrhoidectomy, and bunionectomy after a 200 mg dose, which were compared with a 200 mg dose of CPL-01 in abdominoplasty, herniorrhaphy, and bunionectomy.

[RESULTS] The shape of the CPL-01 systemic concentration curves was consistent across multiple surgical models; however, in LB it was not. The median time to peak concentration (T) of CPL-01 was 8-12 h and the median T of LB varied from < 1 to 36 h. CPL-01 showed tighter ranges in average peak concentration (C) compared with average concentration (C) ratios (less "swing") throughout 72 h, suggesting a more predictable and consistent release over time compared with the biphasic release in LB, with two distinct T peaks.

[CONCLUSIONS] CPL-01 demonstrates a more predictable and consistent release of ropivacaine over time, in contrast to LB's erratic and biphasic release of bupivacaine. If approved, the predictability of CPL-01 PK may give physicians greater confidence in more consistent efficacy and less fear of inadvertent LAST.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 abdominoplasty 복부성형술 dict 1
해부 Liposomal Bupivacaine scispacy 1
해부 long-acting ropivacaine scispacy 1
해부 knee scispacy 1
합병증 bunionectomy scispacy 1
약물 Ropivacaine C0073571
ropivacaine
scispacy 1
약물 Bupivacaine C0006400
bupivacaine
scispacy 1
약물 extended-release scispacy 1
약물 [BACKGROUND AND OBJECTIVE scispacy 1
약물 [CONCLUSIONS] CPL-01 scispacy 1
질환 pain C0030193
Pain
scispacy 1
질환 toxicity C0040539
Toxicity aspects
scispacy 1
기타 CPL-01 scispacy 1

MeSH Terms

Bupivacaine; Ropivacaine; Liposomes; Delayed-Action Preparations; Anesthetics, Local; Humans; Postoperative Pain; Amides; Dose-Response Relationship, Drug

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문